Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jATw9v
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
CBN News Cancer Took Most of His Tongue, but This Pastor Is Still Singing ... CBN News A youth pastor in San Diego, California is not ...
-
Abstract Ocean acidification increases the amount of dissolved inorganic carbon (DIC) available in seawater which can benefit photosynthes...
-
Inhibition of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) signaling is highly effective in a subgroup of no...
-
Abstract Diphenylarsinic acid (DPAA) is an organic arsenic compound used for the synthesis of chemical weapons. We previously found that th...
-
Pugazhenthan Thangaraju, Sajitha Venkatesan, MK Showkath Ali Indian Journal of Community Medicine 2018 43(1):58-59 from #AlexandrosSfa...
-
IJMS, Vol. 18, Pages 1601: Updated Insight into the Physiological and Pathological Roles of the Retromer Complex International Journal of M...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου